Pular para o conteúdo principal
Ranking Invest

LAB - Standard BioTools Inc.

Segmento: HealthcareStandard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.

Análise Ranking Invest

Valuation estimado
$ 359.32 Mi
Valor de Mercado
$ 274.26 Mi
Desconto (AV)-23.7%
IVR
1.31A companhia vale 1,31 vezes o seu valor de mercado atual de acordo com a estimativa do Ranking Invest.
IVR2
-0.76O valuation alternativo equivale a -76% do valor de mercado da companhia.
MLL
-0.76O lucro líquido dos controladores em 16 trimestres equivale a -76% do valor de mercado.
Último Balanço Atualizado: 2T2026

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 539.97 Mi

Dívida Líquida

-$ 270.03 Mi

L4T

$ 84.91 Mi

MM4T

222.22%

Indicadores Básicos

ROE

15.72%

Índices de Previsibilidade

Receita Líquida

F0.32

Lucro

C0.41

Margem

F3.46

Índices de Tendência

Receita Líquida

E-3.06

Lucro

D0.94

Margem

B5.05

Índices de Endividamento

DIV/PAT

-0.50

DIV/L4T

-3.18

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.